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AbsTrACT
background and study aims In the last decade, there 
have been major advances in inflammatory bowel disease 
(IBD) management but their impact on hospital admissions 
requires evaluation. We aim to investigate nationwide 
trends in IBD surgical/medical elective and emergency 
admissions, including endoscopy and cytokine inhibitor 
infusions, between 2003 and 2013.
Patients and methods We used Hospital Episode 
Statistics and population data from the UK Office for 
National Statistics.
results Age-sex standardised admission rates increased 
from 76.5 to 202.9/100 000 (p<0.001) and from 69.5 
to 149.5/100 000 (p<0.001) for Crohn’s disease (CD) 
and ulcerative colitis (UC) between 2003–2004 and 
2012–2013, respectively. Mean length of stay (days) 
fell significantly for elective (from 2.6 to 0.7 and from 
2.0 to 0.7 for CD and UC, respectively) and emergency 
admissions (from 9.2 to 6.8 and from 10.8 to 7.6 for 
CD and UC, respectively). Elective lower gastrointestinal 
(GI) endoscopy rates decreased from 6.3% to 3.7% 
(p<0.001) and from 18.4% to 17.6% (p=0.002) for CD 
and UC, respectively. Elective major abdominal surgery 
rates decreased from 2.8% to 1.0% (p<0.001) and from 
4.9 to 2.4 (p=0.010) for CD and UC, respectively, with 
emergency rates also decreasing significantly for CD. 
Between 2006-2007 and 2012-2013, elective admission 
rates for cytokine-inhibitor infusions increased from 11.1 
to 57.2/100 000 and from 1.4 to 12.1/100 000 for CD and 
UC, respectively.
Conclusions Rising IBD hospital admission rates in 
the past decade have been driven by an increase in the 
incidence and prevalence of IBD. Lower GI endoscopy and 
surgery rates have fallen, while cytokine inhibitor infusion 
rates have risen. There has been a concurrent shift from 
emergency care to shorter elective hospital stays. These 
trends indicate a move towards more elective medical 
management and may reflect improvements in disease 
control.
IntroductIon
Inflammatory bowel disease (IBD) 
comprising Crohn’s disease (CD) and ulcer-
ative colitis (UC) may cause significant 
morbidity and mortality. In the UK, around 
0.25 million people are affected with a prev-
alence of approximately 400 per 100 000 
population. The European incidence of 
IBD has roughly doubled in the past three 
decades coupled with an ageing population, 
in common with many chronic conditions, is 
contributing to a rising prevalence placing a 
substantial economic and clinical burden on 
health services.1–5 IBD diagnosis and manage-
ment requires input from multidisciplinary 
summary box
What is already known about this subject?
 ► Over the period 1989–1990 to 1999–2000, hospital 
admission rates for inflammatory bowel disease 
(IBD) increased by 14% and 6% for Crohn’s disease 
(CD) and ulcerative colitis (UC), respectively.
 ► Over the past decade, treatment of IBD has evolved 
significantly most notably with the introduction of 
cytokine inhibitor therapy.
What are the new findings?
 ► During the period 2003–2004 to 2012–2013, 
admission rates increased for CD and UC whilst 
mean length of stay fell significantly for elective 
and emergency admissions. 
 ► Elective lower-gastrointestinal endoscopy rates 
decreased for both CD and UC as a proportion of all 
IBD admissions.
 ► Elective major abdominal surgery rates for CD and 
UC decreased as a proportion of all IBD admissions.
 ► Between 2006–2007 and 2012–2013, elective 
admission rates for cytokine inhibitor infusions 
increased for CD and UC.
How might it impact on clinical practice in the 
foreseeable future?
 ► Analysing trends in hospital admission rates and 
management approaches for IBD over time allows 
us to understand the potential impact of new 
therapies in improving the quality of care and 
enables more effective evidence-based health 
service planning.
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teams including specialist gastrointestinal physicians 
and surgeons. Patient care is usually overseen by special-
ists in outpatient clinics but some patients may require 
hospital admission for assessment, medical treatment of 
flares and surgery. There is evidence to suggest a reduc-
tion in rates of surgery in recent decades which could 
be seen as a long-term outcome of the ‘treat-to-target’ 
approach of the modern era. Estimates of the risk of 
surgery vary but around 50% of patients with CD and 
15% of patients with UC will undergo surgery within 10 
years of diagnosis.6 Endoscopy is often required diagnos-
tically for disease mapping as well as for chronic disease 
monitoring for severity assessment, cancer surveillance, 
therapeutic interventions such as stricture dilatation and 
to assess mucosal healing in response to therapy.7 8 Addi-
tionally, the European Crohn’s and Colitis Organisation 
guidelines suggest that endoscopic evaluation is required 
for any admission with acute severe UC.8 The goal of care 
is to improve quality of life by inducing and maintaining 
remission and importantly prevent complications of the 
disease that can necessitate surgical intervention. Hence, 
emergency admissions to hospital for surgery may serve 
as a surrogate of disease severity, whereas elective activity 
is likely to reflect proactive surveillance and evidence of 
early intervention to prevent emergency admissions.
We have previously found that hospital admission 
rates for IBD had increased over the previous decade 
1989–1990 to 1999–2000 by 14% and 6% for CD and UC, 
respectively.9 Over the past decade, treatment of IBD has 
evolved significantly most notably with the introduction 
of antitumour necrosis factor (TNF) therapy. The regu-
latory authority responsible for the introduction of new 
drugs in England, the National Institute for Health and 
Care Excellence (NICE), approved episodic treatment 
with infliximab in 2002 and the use of maintenance 
cytokine inhibitor therapy including infliximab for CD 
in 2010.10 11 In addition, NICE released guidance for 
induction of remission in acute severe UC and mainte-
nance cytokine inhibitor therapy including infliximab in 
2015.12 13 In the last decade, there has also been wider 
and earlier use of thiopurines in IBD.14–18 Other develop-
ments which may also have impacted on admission rates 
include the greater involvement of IBD nurse specialists19 
as well as greater patient autonomy with the adoption of 
self-managed action plans.20 21
We hypothesised that these advances in medical thera-
pies and care provision may have resulted in a shift from 
emergency to elective admissions and day case activity. 
As the importance of mucosal healing as a therapeutic 
target has emerged, we also anticipated a parallel increase 
in lower GI endoscopy.22 23 We also anticipate that the 
number of admissions for cytokine inhibitor infusions will 
have increased and that with improved medical treatment 
that surgery rates would have decreased. In this study, we 
therefore aimed to investigate nationwide trends in lower 
GI endoscopic, surgical and medical (including cytokine 
inhibitor infusions) admissions, both elective and emer-
gency, for IBD between 2003–2004 and 2012–2013.
Methods
The hospital admissions data were obtained from Hospital 
Episode Statistics (HES) for the financial years 2003–2004 
to 2012–2013. HES is a national administrative database 
containing patient-level records of all admissions to National 
Health Service (NHS) hospitals in England. Each record 
corresponds to a finished consultant episode, during which 
a patient is under the care of a particular consultant. We 
aggregated these episodes into hospital spells (which equate 
to a hospital admission), covering a patient’s total length of 
stay in a hospital, using the patient identifier, provider code, 
admission date and discharge date.24 Data were provided by 
the NHS Health and Social Care Information Centre (now 
NHS Digital).25
HES contains 20 fields per record for diagnostic codes 
that are defined in the 10th revision of the International 
Statistical Classification of Diseases and Related Health 
Problems (ICD-10).26 We extracted data where an ICD-10 
code for IBD (K50 and K51) was listed as either a primary 
or secondary diagnosis. Where an IBD coded was listed as a 
secondary diagnosis, the clinical steering group (comprising 
AA, CA and RP) reviewed the entire list of coded primary 
diagnoses (n=4847) and, by a consensus process, only diag-
noses deemed related to IBD were included for further 
analysis. A full list of the diagnoses chosen by the clinical 
steering group, selected when the diagnosis was chosen by 
two or more group members, is shown in the online supple-
mentary appendix. The clinical steering group comprised 
practising clinicians with a subspecialty interest in IBD.
hospital admission rates
We first calculated crude hospital admission rates by dividing 
the number of admissions by mid-year population estimates 
for England obtained from the Office for National Statis-
tics27 and all rates are expressed as admissions per 100 000 
population. We used the mid-year population estimate for 
the calendar year overlapping the majority (9 months) of 
the financial year. All rates were age and sex standardised: 
direct standardisation was carried out to determine age-sex 
standardised rates which were calculated by applying the 
rates of each age-sex group (0–14, 15–24, 25–39, 40–59 and 
60 years and over; male and female) to the 2003 population 
in England. Lengths of stay in hospital were examined using 
mean spell duration from the HES data. Admissions were 
additionally categorised into those which were elective or 
emergency.
endoscopy, surgery and infusions
We examined the hospital age-sex standardised admis-
sions that involved a lower endoscopic procedure. We 
considered the codes G14–G19, G42–G47, G54, G55, 
G64, G65, G79, G80, H20–H28 and H68–H70 as lower 
endoscopic procedures.
We calculated the age-sex standardised inpatient 
hospital admission rates, both emergency and elective, 
for CD or UC that involved a surgical procedure (see 
above regarding selection procedure). CD surgery was 
subcategorised as either major (intestinal) abdominal 
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surgery or perianal surgery. HES records operation codes 
according to the OPCS Classification of Interventions 
and Procedures (OPCS-4).28 G58–59, G63, G69–75, G78, 
H04–13 were considered as a major abdominal surgery 
for CD. H33, H41, H46, H47–49, H55–56 were consid-
ered as perianal surgery for CD. H04–H11 were consid-
ered as surgical procedures for UC.
We also examined admissions for therapeutic infusion. 
We considered codes X28.1, X28.2, X28.8, X28.9, X29.2, 
X29.3, X29.8, X29.9 and X92.1 to identify infusions of a 
therapeutic substance including administration of anti-
cytokine treatment codes for which a specific code was 
introduced in 2006-2007.
statistical analysis
We used negative binomial regression to test for an associ-
ation between hospital admission rates and financial year, 
adjusting for age and sex group. Linear regression adjusting 
for age and sex was used for the analyses of changes in mean 
lengths of stay. The analysis was conducted in Stata V.14.0.
ethical considerations
Imperial College London has permission to use HES data 
for research from the NHS Health and Social Care Infor-
mation Centre (now NHS Digital).
results
hospital admission rates
Age-specific hospital admission rates
For all age groups, there was an increase in hospital 
admission rates (including both elective and emergency 
admissions) during the study period from 2003-2004 to 
2012-2013 (table 1). CD admission rates increased almost 
threefold from 76.5 to 202.9/100 000 and doubled for 
UC from 69.5 to 149.5/100 000 population. The rate 
of increase in admission rates was greatest in the group 
aged 15–24 years for CD rising from 77.3 to 239.0/100 
000 and in the group aged 25–39 years for UC from 61.2 
to 147.1/100 000.
CD admission rates were highest in the group aged 
25–39 years for most of the study period except for 2003–
2004 and 2009–2010 when admission rates were highest 
in patients aged 60 and above. UC admission rates 
were consistently highest in patients aged 60 and above 
throughout the study period.
Mean length of stay
The mean length of stay for CD and UC admissions, for 
both elective and emergency admissions, has fallen from 
2003–2004 to 2012–2013. The relative reduction in length 
of stay for elective admissions was greater than for emer-
gency admissions reflecting the increase in day case activity. 
Length of stay for elective admissions fell from 2.6 to 0.7 days 
for CD and from 2.0 to 0.7 days for UC. Length of stay for 
emergency admissions fell from 9.2 to 6.8 days for CD and 
from 10.8 to 7.6 days for UC. The proportion of elective 
admissions with a length of stay of less than 1 day increased 
from 68.9% to 89.2% (p<0.001) and from 78.5% to 88.1% 
(p<0.001) for CD and UC, respectively. The proportion of 
emergency admissions with length of stay of less than 1 day 
increased from 10.1% to 13.9% (p<0.001) and from 8.4% 
to 10.9% (p<0.001) for CD and UC, respectively.
elective and emergency admissions
During the study period, hospital admission rates 
increased significantly for CD and UC for both emergency 
Table 1 Age-sex standardised and age-specific hospital admission rates* for Crohn’s disease (CD) and ulcerative colitis (UC)
Age (years)
Year
P values 
trend
2003/
2004
2004/
2005
2005/
2006
2006/
2007
2007/
2008
2008/
2009
2009/
2010
2010/
2011
2011/
2012
2012/
2013
CD
  0–14 17.2 19.2 21.9 23.1 25.3 30.1 55.1 31.2 36.2 40.3 <0.001
  15–24 77.3 85.0 103.4 115.8 127.7 155.0 177.2 191.9 214.1 239.0 <0.001
  25–39 93.7 101.5 126.0 146.9 161.9 176.8 176.2 227.4 241.1 258.5 <0.001
  40–59 88.5 98.0 113.4 127.3 145.0 163.4 177.6 204.1 217.5 236.0 <0.001
  60+ 95.2 99.9 113.3 125.7 136.7 152.8 189.9 202.1 213.4 223.7 <0.001
  Overall CD 76.5 83.1 98.1 110.7 122.8 138.7 157.4 175.6 188.2 202.9 <0.001
UC
  0–14 8.0 8.1 9.6 9.9 11.1 12.7 20.0 14.2 15.3 15.8 <0.001
  15–24 41.9 41.4 50.1 54.6 57.7 62.8 79.2 78.1 85.7 98.8 <0.001
  25–39 61.2 66.4 75.7 84.9 93.8 104.0 98.8 127.3 132.1 147.1 <0.001
  40–59 90.9 92.0 104.2 112.0 122.7 134.6 134.9 160.3 167.1 178.3 <0.001
  60+ 122.0 130.0 148.2 164.0 179.3 199.9 225.6 238.7 249.0 265.9 <0.001
  Overall UC 69.5 72.5 82.9 90.9 99.4 110.0 117.6 132.1 138.1 149.5 <0.001
*Rates per 100 000 population were calculated by dividing the number of admissions by mid-year population estimates for England obtained 
from the Office for National Statistics.
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and elective admissions (table 2). The increase in elective 
hospital admission rates was proportionally greater for 
CD admissions compared with UC.
Elective admission rates for CD increased from 39.6 to 
137.7/100 000 (p<0.001). During the same period, elec-
tive admission rates for UC also rose significantly from 43.5 
to 99.9/100 000 (p<0.001). Emergency admission rates 
for CD increased from 36.9 to 65.2/100 000 (p<0.001) 
during the period from 2003–2004 to 2012–2013. During 
the same period, emergency admission rates for UC also 
rose significantly from 26.0 to 49.6/100 000 (p<0.001). 
The percentage of surgical admissions, as a proportion 
of all IBD admissions, fell for all admission types (elec-
tive and emergency) and for both CD and UC during 
the study period. The percentage of surgical emergency 
admissions fell from 6.5% to 4.0% for CD (p=0.001) and 
from 4.6% to 2.2% for UC (p<0.001). The percentage of 
surgical elective admissions fell from 12.1% to 4.5% for 
CD (p<0.001) and from 7.8% to 3.6% for UC (p<0.001).
endoscopy, surgery and infusions
As a proportion of IBD admissions, elective endoscopy 
rates have fallen for CD and UC from 6.3% to 3.7% 
(p<0.001) and 18.4% to 17.6% (p=0.002), respectively 
(table 3). Emergency endoscopy rates have also fallen 
for UC from 43.9% to 38.6% (p<0.001) but did not 
reach statistical significance for CD from 4.1% to 1.9% 
(p=0.754).
CD surgery rates, as a proportion of IBD admissions, for 
both major abdominal and perianal surgery decreased 
significantly during the study period (table 4). CD emer-
gency perianal surgery and major surgery reduced from 
0.4% to 0.2% (p=0.001) and 4.5% to 2% (p<0.001), 
respectively. CD elective perianal surgery and major 
surgery reduced from 1.8% to 1.1% (p<0.001) and 2.8% 
to 1.0% (p<0.001), respectively. UC surgery rates fell 
significantly for elective admissions from 4.9% to 2.4% 
(p=0.010) but not significantly for emergency admissions 
from 1.8% to 0.8% (p=0.146).
Infusion rates for both CD and UC increased during 
the study period regardless of admission type (table 5). 
The proportion of planned infusions was much greater 
than for emergency infusions for both conditions. Elec-
tive admissions for cytokine inhibitor infusions increased 
between 2006–2007 (following the introduction of a 
specific code) and 2012–2013 from 11.1 to 57.2/100 000 
(p<0.001) and from 1.4 to 12.1/100 000 (p<0.001) for 
CD and UC, respectively. Emergency admissions for cyto-
kine inhibitor infusions increased from 0.5 to 1.9/100 
Table 2 Age-sex standardised elective and emergency hospital admission rates* for Crohn’s disease (CD) and ulcerative 
colitis (UC) 2003/2004–2012/2013 and surgical admission as a proportion of all inflammatory bowel disease admissions
2003/
2004
2004/
2005
2005/
2006
2006/
2007
2007/
2008
2008/
2009
2009/
2010
2010/
2011
2011/
2012
2012/
2013
P values 
trend
CD
  Emergency 
(total)
36.9 39.8 44.6 46.2 48.2 52.4 58 62.4 62.7 65.2 <0.001
   Medical 34.5 37.4 42 43.9 45.8 49.9 55.4 59.8 60.1 62.6 <0.001
   Surgical 2.4 2.4 2.6 2.3 2.4 2.5 2.6 2.6 2.6 2.6 0.006
   % Surgical 6.5 6 5.8 5 5 4.8 4.5 4.2 4.1 4 0.001
  Elective
  (total)
39.6 43.3 53.5 64.5 74.6 86.3 99.4 113.2 125.5 137.7 <0.001
   Medical 34.8 38.5 48.5 59.4 69.2 80.6 93.6 107.2 119.2 131.5 <0.001
   Surgical 4.8 4.8 5 5.1 5.4 5.7 5.8 6 6.3 6.2 <0.001
   % Surgical 12.1 11.1 9.3 7.9 7.2 6.6 5.8 5.3 5 4.5 <0.001
UC
  Emergency 
(total)
26.0 28.4 32.1 33 35.1 38.3 41.4 45.8 45.7 49.6 <0.001
   Medical 24.8 27.1 30.8 31.8 33.9 37 40.2 44.5 44.4 48.5 <0.001
   Surgical 1.2 1.3 1.3 1.2 1.2 1.3 1.2 1.3 1.3 1.1 0.146
   % Surgical 4.6 4.6 4 3.6 3.4 3.4 2.9 2.8 2.8 2.2 <0.001
  Elective
  (total)
43.5 44.1 50.8 57.9 64.3 71.7 76.2 86.3 92.4 99.9 <0.001
   Medical 40.1 40.8 47.2 54.7 60.8 68 72.5 82.4 88.6 96.3 <0.001
   Surgical 3.4 3.3 3.6 3.2 3.5 3.7 3.7 3.9 3.8 3.6 0.01
   % Surgical 7.8 7.5 7.1 5.4 5.2 5.2 5.1 4.5 4.1 3.6 <0.001
*Rates per 100 000 population were calculated by dividing the number of admissions by mid-year population estimates for 
England obtained from the Office for National Statistics.
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000 (p<0.001) and from 0.1 to 1.0/100 000 (p<0.001) for 
CD and UC, respectively.
dIscussIon
Main findings
Total IBD hospital admission rates have more than 
doubled from 2003–2004 to 2012–2013 driven by 
substantial rises in elective admissions particularly for 
lower GI endoscopy and cytokine inhibitor infusions. 
While medical admissions have risen steeply, surgical 
admissions have plateaued with a significant reduction in 
the rate of emergency and elective surgery for CD and 
a reduction in the rate of elective surgery for UC over 
the decade despite an increasing incidence and severity 
of disease phenotype in European populations.4 5 29 
Mean length of stay has decreased for both elective and 
emergency admissions. These trends suggest a shift from 
reactive emergency management of IBD towards more 
planned day case based activity. There has also been a 
reduction in elective lower GI endoscopy for CD and 
UC as a proportion of all IBD admissions over the last 
decade. Emergency endoscopy rates fell significantly for 
UC but not CD over the study period. The rise in cyto-
kine inhibitor infusions (infliximab) reflects the emer-
gence and increasing use of these agents over the period 
initially for CD and more recently for UC. These findings 
reveal important changes in the approach to the manage-
ment of IBD over the past decade with a shift to shorter, 
elective, day case medical admissions.
Findings in relation to other studies
Hospital admission rates for IBD have largely been 
reported to be rising in Europe and North America for 
some years but are not consistent.30–34 All these studies 
predate our findings which analysed a period during 
which there has been significant changes in the avail-
ability of newer medications. We found overall IBD 
admissions more than doubled in the decade between 
2003–2004 and 2012–2013. This is striking compared 
with previous studies that found much smaller increases 
in admission in the nineties.9 Overall, with the advent of 
national screening measures, lower GI endoscopy rates 
Table 3 Percentage proportion of lower gastrointestinal endoscopy procedures during emergency and elective inflammatory 
bowel disease admissions
2003/
2004
2004/
2005
2005/
2006
2006/
2007
2007/
2008
2008/
2009
2009/
2010
2010/
2011
2011/
2012
2012/
2013
P values 
for trend
Crohn’s disease
  Emergency 4.1 3.9 3.3 2.8 2.8 2.5 2.3 2.2 1.9 1.9 0.754
  Elective 6.3 6.2 5.7 5.1 4.8 4.6 4.4 4.0 3.8 3.7 <0.001
Ulcerative colitis
  Emergency 43.9 42.7 41.7 43.3 42.7 43.3 41.4 40.0 39.7 38.6 <0.001
  Elective 18.4 16.8 16.5 17.4 17.3 17.9 17.3 17.3 17.7 17.6 0.002
Percentage for Crohn’s disease or ulcerative colitis admissions—p value from linear regression.
Table 4 Percentage proportion of surgical procedures during emergency and elective inflammatory bowel disease 
admissions
Year
P value 
for trend
2003/
2004
2004/
2005
2005/
2006
2006/
2007
2007/
2008
2008/
2009
2009/
2010
2010/
2011
2011/
2012
2012/
2013
Crohn’s disease
  Perianal surgery
   Emergency 0.4 0.4 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.001
   Elective 1.8 1.7 1.6 1.4 1.4 1.4 1.3 1.2 1.2 1.1 <0.001
  Major surgery
   Emergency 4.5 4.1 3.6 3.2 3.0 2.8 2.4 2.2 2.2 2.0 <0.001
   Elective 2.8 2.5 2.3 1.8 1.7 1.5 1.4 1.2 1.1 1.0 <0.001
Ulcerative colitis
  Surgery
   Emergency 1.8 1.8 1.5 1.4 1.2 1.2 1.0 0.9 0.9 0.8 0.146
   Elective 4.9 4.6 4.4 3.5 3.5 3.3 3.1 2.9 2.7 2.4 0.010
Percentage for Crohn’s disease or ulcerative colitis admissions—p value from linear regression.
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have previously been reported to be rising with an indica-
tion that this is associated with reduction in mortality at 
the population level.35 36 Regarding lower GI endoscopy 
rates for patients with IBD, there is a lack of published 
literature. We found a significant fall in the proportion of 
lower GI endoscopy rates for both emergency and elective 
UC admissions and for elective CD admissions over the 
10-year period. This may reflect improved disease control 
as a result of medical advancements with a reduction in 
disease flares requiring endoscopic evaluation. These 
findings suggest that the overall increase in demand for 
endoscopic services over recent years is a result of the 
increasing incidence and prevalence of IBD.
In the USA, there have been three analyses using the 
National inpatient sample (NIS), in many ways compa-
rable to HES, with all these studies indicating a rise in 
admissions.32–34 Most recently, non-surgical admission 
rates increased by 68% and 52% for CD and UC, respec-
tively, between 2004 and 2007.32 However, a study from 
Northern California, from the health maintenance 
organisation Kaiser Permanente, which has arguably 
similar constraints on healthcare provision to the NHS, 
found a 33% and 29% decrease in hospital admission 
rates for CD and UC, respectively, between 1998 and 
2005 but importantly the study did not include day case 
activity.31. An Irish study, of both day cases and inpatients, 
also reported an overall rise in national IBD admission 
rates between 1996 and 2001.31 The rises are consistent 
with a general trend of rising hospital admissions in 
developed countries,37 among an ageing population with 
increasingly complex multimorbidity. Superimposed on 
this trend is rising incidence of IBD including a propor-
tionally greater rise in children and young people with 
IBD among whom the condition has a more severe 
phenotype.2 4 5 38 An additional explanation for rises in 
admissions may be improved ascertainment over the 
study period. Finally, the rises may reflect changing clin-
ical practice, in particular, the advent of biologic drugs 
that may have driven the shift to shorter more frequent 
elective day case activity.
We examined surgery rates between 2003-2004 and 
2012-2013, as a proportion of all IBD admissions and 
found a significant reduction in CD surgery rates, both 
perianal and major surgery, for emergency and elective 
admissions. UC elective surgery rates also fell signifi-
cantly but there was no significant reduction in emer-
gency surgery. An analysis of rates of surgery in the USA 
between 1998 and 2012 showed a similar decrease in 
admissions for CD-related and UC-related bowel surgery 
of 4.9% and 3.3% with the greater proportion related to 
a reduction in emergency surgery.32 39
The proportion of day case activity rose and there was 
an overall reduction in inpatient length of stay suggesting 
patients now have more frequent but shorter hospital 
spells. In keeping with our findings, day case admissions 
have also risen substantially in Ireland.31 This may, in 
part, reflect the greater use of day case admissions for 
anticytokine infusions in recent years. The greater rise 
in elective admission rates compared with emergency 
admissions may also reflect a more general shift in 
chronic disease management in the UK national health 
service and elsewhere directed towards better disease 
control through outpatient care and planned elective 
procedures replacing emergency activity.40–42 We found 
length of stay for IBD emergency admissions fell from 9.2 
to 6.8 days and 10.8 to 7.6 days for CD and UC during 
the study period depending on the admission type. In 
the USA, over the same time period, average length of 
stay for patients with either UC or CD has also fallen by a 
similar magnitude.32 34
The observed trends in our study and others are 
reflected in a meta-analysis of studies from Europe, 
North America and Asia that found a significant drop 
in IBD-related surgery over the past five decades.6 A 
national Danish population-based cohort also report a 
decreasing requirement for IBD surgery over the past 
30 years.43 A more recent analysis from 2002 to 2010 
in Canada also showed an overall reduction in surgical 
resection rates with elective operations being more 
commonly performed than emergency surgery.44 Studies 
show the increasing and earlier use of thiopurines and 
Table 5 Elective and emergency hospital admissions* with any infusion or cytokine inhibitor infusion for Crohn’s disease and 
ulcerative colitis
Mode of 
admission
Year
P value 
for trend
2006/
2007
2007/
2008
2008/
2009
2009/
2010
2010/
2011
2011/
2012
2012/
2013
Crohn’s disease
Cytokine inhibitor infusions Emergency 0.5 0.8 1.3 1.4 1.4 1.5 1.9 <0.001
Elective 11.1 19.5 26.7 33.5 40.3 46.1 57.2 <0.001
Ulcerative Colitis
Cytokine inhibitor infusions Emergency 0.1 0.2 0.3 0.3 0.5 0.6 1.0 <0.001
Elective 1.4 3.5 4.2 5.2 7.3 9.2 12.1 <0.001
*Rates per 100 000 population were calculated by dividing the number of admissions by mid-year population estimates for England obtained 
from the Office for National Statistics.
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maintenance cytokine inhibitor therapy is associated with 
a reduced need for surgery in CD.16 45 We postulate that 
as biological therapies become increasingly established, 
we will see further evidence of a fall in rates of surgery in 
IBD in the future.14–16 46–49
We found an increase in the use of infusions largely 
related to anticytokine infusions (infliximab) in England 
during the study period. Our study is the first nationwide 
study to characterise temporal trends in infliximab use. 
The rising trend reflects the increasing use of infliximab 
in the latter half of the study period although mainte-
nance therapy for CD was not finally approved for use in 
the UK until towards the end of the study period.11 The 
use of cytokine inhibitor agents as a maintenance treat-
ment in the management of UC was not approved until 
after the end of the study period in 2015.13 However, the 
use of infliximab, as a second-line option, for the induc-
tion of remission in acute severe colitis was approved in 
the UK in 2008.12 This difference in the availability of 
anti-TNFs for the treatment of UC compared with CD is 
reflected in the much smaller number of cytokine inhib-
itor infusions for UC. Our findings mirror the interim 
UK biologics audit, a study reporting data derived from 
the majority of the nation’s IBD units, indicated a rela-
tively modest uptake of cytokine inhibitor use in 2010 but 
temporal trends were not reported.50 51
Accumulating evidence suggests that long-term cyto-
kine inhibitor treatment may significantly reduce the 
need for surgery in CD,45 52 53 although the evidence in 
UC is possibly less compelling.54 55 Data from Canada, 
Hungary and the UK show that surgical rates were already 
falling before biological therapy came into widespread 
use.14 15 46 47 We and others have reported data supporting 
an important role for thiopurines in reducing the long-
term need for surgery.16
study strengths and limitations
HES maintains a comprehensive data set of all admissions 
to NHS hospitals in England and has previously been 
used in the field of IBD research.56 57 Our national study 
includes all hospitals in England, and its size and repre-
sentativeness mean that it overcomes potential biases 
of previous regional referral centre cohort studies.56 
However, in common with other observational studies 
using large administrative databases, the quality of the 
coding of diagnoses and surgery relies on data entry 
performed locally at hospital level with the potential for 
misclassification. The precision and depth of coding may 
have changed over the decade of study and might, at least 
in part, account for the observed rise in admissions.58 
Furthermore, some procedures may not have been 
coded with the relevant accompanying IBD code. We 
have attempted to improve the ascertainment of IBD-re-
lated admissions by including IBD admissions coded as 
either primary or secondary diagnoses and, in the case 
of the latter, admissions were only included where the 
primary diagnosis was considered relevant to IBD by a 
clinical steering group. Unfortunately, HES does not 
provide data for adalimumab which is a self-administered 
subcutaneous injection that does not require admis-
sion. Finally, we did not detail trends in specific surgical 
procedures but we have distinguished major abdominal 
(intestinal) surgery from perianal surgery in CD which is 
arguably the most clinically relevant categorisation. HES 
is an administrative dataset so causal relations between 
trends in admissions and changes in IBD management 
cannot be drawn merely observed associations.
Implications and future research
Our findings, indicating a shift towards more planned 
and shorter elective inpatient care is a considerable 
improvement for patients who previously required long 
hospital admissions. The general fall in endoscopy and 
surgery rates coupled with a rise in cytokine inhibitor use 
may suggest improved disease control. The shift from 
emergency to elective activity with shorter length of stay 
will have reduced costs substantially. That being said, 
cost savings are likely offset by the increasing expense 
of biologics as underscored by the Dutch IBD health-
care cost analysis COIN study as well as the rising inci-
dence and prevalence of IBD.59 Further health economic 
studies, particularly with regard to avoidable emergency 
care, would be enlightening.
Our findings address a gap in information identified 
by the quality agenda set by the published UK IBD stan-
dards60 61 and provide valuable information for future 
health service planning. The fact that surgery rates 
are falling despite the rising incidence and prevalence 
of this chronic disorder suggests that there have been 
improvements in the quality of care and efficacy of treat-
ment provided to patients with IBD but further work 
is needed to elucidate this further. It is probable that 
recent advances in the management of IBD including 
the substantial increase in the use of thiopurines and 
cytokine inhibitor therapy may have impacted on long-
term outcomes in this condition and with it a reduction 
in long-stay admissions. Further, IBD time trends analysis 
in the forthcoming decade will shed further light on the 
impact of these agents.
conclusIon
Rising IBD hospital admission rates in the past decade 
have been driven by an increase in the incidence and 
prevalence of IBD. Lower GI endoscopy and surgery rates 
have fallen as a proportion of all IBD admissions, while 
cytokine inhibitor infusion rates have risen. There has 
been a concurrent shift from emergency care to much 
shorter elective hospital stays. These trends indicate a 
move towards more elective medical management and 
may reflect improvements in disease control.
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